{"success":true,"data":{"pressRelease":{"id":"7199","rtpr_id":"nGNX4JBp0n","ticker":"VTAK","exchange":"NYSE American","all_tickers":["VTAK"],"title":"Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting","author":"Globe Newswire","published_at":"2026-04-23T16:00:00.432Z","article_body":"VIVO System to be featured in educational sessions at HRS\n\nAccepted manuscripts for LockeT and VIVO are now published and available\nonline\n\nFORT MILL, S.C., April 23, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc.\n(VTAK - NYSE/American), a US based medical device company focused on\ndeveloping technologically advanced products for the cardiac electrophysiology\nmarket announced their attendance at the 47(th) annual Heart Rhythm Society\n(HRS) meeting. The HRS meeting will take place from April 24(th) to the 27(th)\nin Chicago, Illinois.\n\nHRS announced\n(https://www.globenewswire.com/Tracker?data=Mry7orb309Dm4rMH0Ube1noZHNIg6IIS0FVHZYyyRbhF7C5s7zEMxawxT7sUMHWXj2dkAE7IdDBRoUJqF5Tnmb3l3UB7Ql596yjD0huC3r5E1jg8SvDh36WLXE2M53Gd)\nthat the 47(th) conference will bring together more than 10,000 professionals\nworldwide for a global exchange of science and innovation advancing\nelectrophysiology (EP). Designed by and for heart rhythm professionals, the\nmeeting features almost 2,000 sessions, posters, roundtables, and hands-on\nexperiences highlighting the latest breakthroughs in arrhythmia care.\n\nHeart Rhythm 2026 received the highest number of abstract submissions in its\nhistory, including a fourfold increase in late-breaking science over the past\ndecade, a testament to the rapid growth in the EP field. The meeting continues\nto serve as a premier forum where practice-changing research is unveiled,\nsparking the most important conversations and fueling unprecedented scientific\nadvancement across the field.\n\nNew Data Presented at the Heart Rhythm Society Meeting\nOne abstract on Catheter Precision’s VIVO system was accepted and the data\nwill be presented in a poster format on Friday, April 24. In addition,\nProfessor Tarvinder Dhanjal\n(https://www.globenewswire.com/Tracker?data=zPvEJk8bsYxNpWO76d-Kd9znoaHbWBRwD7lJa9xJMBdTJN9CyKR1M0hzcAxpNFbcBPPRreZC2ZnHnMetdj0kbMmdJwQ1b0_YetD8_-SUQz-rsF9k_7u0IEr-Wt_-V-4pw7xz9PnNj6M22eynnp0_CQ==)\nwas invited to speak during a core session on the VIVO system on Saturday,\nApril 25.\n* Friday April 24, 2026 – Ventricular arrythmia localization using implanted\ncardioverter defibrillator intracardiac electrogram recordings * This study is\nnovel and the first to demonstrate feasibility of using intra-cardiac\nelectrodes rather than a surface 12-lead ECG to accurately identify\nventricular tachycardia (VT)\n* While more research is being conducted, this feasibility indicated VIVO may\nprovide patients with safer VT diagnosis and allow treatment for a currently\ndifficult to treat patient population\n\n\n \n* Saturday, April 25, 2026 – Leveraging recorded CIED and EKG data in\ncreating integrated models for accurate localization of arrythmias with real\ntime 3D mapping * This session will highlight VIVO’s benefits for improved\nworkflow and accurate localization to improve the identification of areas of\ninterest for ventricular ablation procedures\nNew Publications for Both LockeT and VIVO are Available Online\nRecently, Catheter Precision announced the acceptance of two publications, one\nfor LockeT and one for VIVO, in leading electrophysiology journals.\n\nNew data demonstrating the benefits of LockeT in large-bore electrophysiology\nprocedures was accepted by the Journal of Cardiovascular Electrophysiology.\nThis study, found here\n(https://www.globenewswire.com/Tracker?data=iqA1jf3qZgAWQ9IZMalRv2xDmd9awmxXw_dPxuw8dL_e6WhsOTzhh8mHJUZGx9nhmQQJMdEH0BQLVek6Sx1yhrVqYe1tKVCIV1qC0Pktnnc0a1AnnFueCiMMabR7RMfA),\nincluded 139 patients and concluded that LockeT demonstrated high procedural\nsuccess, rapid hemostasis, early ambulation, and low complication rates for\nvenous closure following EP procedures requiring large-bore venous access\n(LBVA). These findings support LockeT as a feasible and effective venous\nclosure strategy in contemporary EP practice.\n\nA new VIVO study was accepted by leading European journal, EP Europace\n(https://www.globenewswire.com/Tracker?data=EJZq-DbuhX-w7trdigxRDrdoyfpwCDSyiHBiDevmJQrMW8ZKzRGqN2hLVphMVVjM_5yzm_-r57wUx-hQig5LGwXBQpQbi-cm6xhcdLu7xrVCBoq8NaTAmBlIsvku9LPGGAOJqfDGQHQSjNUtS6l1Nw==).\nThis study included 31 patients and mapped 48 VTs with VIVO and standard of\ncare electroanatomical mapping systems to determine accuracy. The study\n(https://www.globenewswire.com/Tracker?data=heLYyIbgQvi7QEJlN6JmiwrYVOuDhWXvjNS7CwhlVXUY3MqfOt03QkwS1-PuUv_BOdMaZnG9YEX3Q09r0LUC_llZlbHpu1hDa_VXXQ49cGc2o5kmbDo97vNEmooqOhasM_1P_OK-qRfcifyFgSmh0krZ0cQzpW_ZURU6OWHsQWvDuOGg5ZoGF0R9tVHRxpCE)\nconcluded that VIVO can accurately predict the arrhythmogenic substrate for\nscar-dependent VT and incorporation of VIVO mapping to conventional VT\nablation workflows improves procedural efficiency.\n\nDavid Jenkins, CEO of Catheter Precision, said, “Having an abstract accepted\nat any conference is an accomplishment. Somewhere around 50% of abstracts are\naccepted and knowing that this is the largest submission of ground-breaking\ndata ever at HRS means that the research and products resonate with the\nabstract committee. Further, to have one of our VIVO users be asked to present\na session highlights the excitement around not just the product, but the\nbenefits that VIVO brings to patients, hospitals and physicians. We anticipate\nHRS 2026 to be a symposium where we not only demonstrate our products to new\nand existing customers, but where we can share new and exciting research, like\nthe new peer reviewed publications, that validate our products to the EP\ncommunity.”\n\nAbout LockeT\nCatheter Precision’s LockeT is a suture retention device intended to assist\nin wound closure after percutaneous venous punctures. LockeT is a Class 1\ndevice registered with the FDA.\n\nAbout VIVO\nCatheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive\n3D imaging system that enables physicians to identify the origin of\nventricular arrhythmias pre-procedure, thereby streamlining workflow and\nreducing procedure time. VIVO has received marketing clearance from the U.S.\nFDA and has the CE mark.\n\nAbout Catheter Precision\nCatheter Precision is an innovative U.S.-based medical device company bringing\nnew solutions to market to improve the treatment of cardiac arrhythmias. It is\nfocused on developing groundbreaking technology for electrophysiology\nprocedures by collaborating with physicians and continuously advancing its\nproducts.\n\nCautionary Note Regarding Forward-Looking Statements\nStatements in this press release may contain “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995\nthat are subject to substantial risk and uncertainties. Forward-looking\nstatements can be identified by words such as “believe,” “anticipate,”\n“may,” “might,” “can,” “could,” “continue,” “depends,”\n“expect,” “expand,” “forecast,” “intend,” “predict,”\n“plan,” “rely,” “should,” “will,” “may,” “seek,” or\nthe negative of these terms and other similar expressions, although not all\nforward-looking statements contain these words.  These forward-looking\nstatements include, but are not limited to, statements regarding our\nanticipation HRS 2026 will be a symposium where we not only demonstrate our\nproducts to new and existing customers, but where we can share new and\nexciting research, like the new peer-reviewed publications, that validate our\nproducts to the EP community. The Company’s expectations and beliefs\nregarding these matters may not materialize. Actual outcomes and results may\ndiffer materially from those contemplated by these forward-looking statements\nas a result of uncertainties, risks and changes in circumstances, including\nbut not limited to risks and uncertainties included under the caption “Risk\nFactors” in the Company’s Form 10-K filed with the SEC and available at\nwww.sec.gov.\n\nThe forward-looking statements included in this communication are made only as\nof the date hereof. The Company assumes no obligation and does not intend to\nupdate these forward-looking statements, except as required by law.\n\nCONTACTS:\n\nAt the Company\nDavid Jenkins\n973-691-2000\nIR@catheterprecision.com\n\n# # #\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cb9f10dc-be78-4c7c-a235-81bfdd77f03c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4JBp0n","title":"Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting","author":"Globe Newswire","ticker":"VTAK","created":"2026-04-23T16:00:00.432Z","tickers":["VTAK"],"exchange":"NYSE American","article_body":"VIVO System to be featured in educational sessions at HRS\n\nAccepted manuscripts for LockeT and VIVO are now published and available\nonline\n\nFORT MILL, S.C., April 23, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc.\n(VTAK - NYSE/American), a US based medical device company focused on\ndeveloping technologically advanced products for the cardiac electrophysiology\nmarket announced their attendance at the 47(th) annual Heart Rhythm Society\n(HRS) meeting. The HRS meeting will take place from April 24(th) to the 27(th)\nin Chicago, Illinois.\n\nHRS announced\n(https://www.globenewswire.com/Tracker?data=Mry7orb309Dm4rMH0Ube1noZHNIg6IIS0FVHZYyyRbhF7C5s7zEMxawxT7sUMHWXj2dkAE7IdDBRoUJqF5Tnmb3l3UB7Ql596yjD0huC3r5E1jg8SvDh36WLXE2M53Gd)\nthat the 47(th) conference will bring together more than 10,000 professionals\nworldwide for a global exchange of science and innovation advancing\nelectrophysiology (EP). Designed by and for heart rhythm professionals, the\nmeeting features almost 2,000 sessions, posters, roundtables, and hands-on\nexperiences highlighting the latest breakthroughs in arrhythmia care.\n\nHeart Rhythm 2026 received the highest number of abstract submissions in its\nhistory, including a fourfold increase in late-breaking science over the past\ndecade, a testament to the rapid growth in the EP field. The meeting continues\nto serve as a premier forum where practice-changing research is unveiled,\nsparking the most important conversations and fueling unprecedented scientific\nadvancement across the field.\n\nNew Data Presented at the Heart Rhythm Society Meeting\nOne abstract on Catheter Precision’s VIVO system was accepted and the data\nwill be presented in a poster format on Friday, April 24. In addition,\nProfessor Tarvinder Dhanjal\n(https://www.globenewswire.com/Tracker?data=zPvEJk8bsYxNpWO76d-Kd9znoaHbWBRwD7lJa9xJMBdTJN9CyKR1M0hzcAxpNFbcBPPRreZC2ZnHnMetdj0kbMmdJwQ1b0_YetD8_-SUQz-rsF9k_7u0IEr-Wt_-V-4pw7xz9PnNj6M22eynnp0_CQ==)\nwas invited to speak during a core session on the VIVO system on Saturday,\nApril 25.\n* Friday April 24, 2026 – Ventricular arrythmia localization using implanted\ncardioverter defibrillator intracardiac electrogram recordings * This study is\nnovel and the first to demonstrate feasibility of using intra-cardiac\nelectrodes rather than a surface 12-lead ECG to accurately identify\nventricular tachycardia (VT)\n* While more research is being conducted, this feasibility indicated VIVO may\nprovide patients with safer VT diagnosis and allow treatment for a currently\ndifficult to treat patient population\n\n\n \n* Saturday, April 25, 2026 – Leveraging recorded CIED and EKG data in\ncreating integrated models for accurate localization of arrythmias with real\ntime 3D mapping * This session will highlight VIVO’s benefits for improved\nworkflow and accurate localization to improve the identification of areas of\ninterest for ventricular ablation procedures\nNew Publications for Both LockeT and VIVO are Available Online\nRecently, Catheter Precision announced the acceptance of two publications, one\nfor LockeT and one for VIVO, in leading electrophysiology journals.\n\nNew data demonstrating the benefits of LockeT in large-bore electrophysiology\nprocedures was accepted by the Journal of Cardiovascular Electrophysiology.\nThis study, found here\n(https://www.globenewswire.com/Tracker?data=iqA1jf3qZgAWQ9IZMalRv2xDmd9awmxXw_dPxuw8dL_e6WhsOTzhh8mHJUZGx9nhmQQJMdEH0BQLVek6Sx1yhrVqYe1tKVCIV1qC0Pktnnc0a1AnnFueCiMMabR7RMfA),\nincluded 139 patients and concluded that LockeT demonstrated high procedural\nsuccess, rapid hemostasis, early ambulation, and low complication rates for\nvenous closure following EP procedures requiring large-bore venous access\n(LBVA). These findings support LockeT as a feasible and effective venous\nclosure strategy in contemporary EP practice.\n\nA new VIVO study was accepted by leading European journal, EP Europace\n(https://www.globenewswire.com/Tracker?data=EJZq-DbuhX-w7trdigxRDrdoyfpwCDSyiHBiDevmJQrMW8ZKzRGqN2hLVphMVVjM_5yzm_-r57wUx-hQig5LGwXBQpQbi-cm6xhcdLu7xrVCBoq8NaTAmBlIsvku9LPGGAOJqfDGQHQSjNUtS6l1Nw==).\nThis study included 31 patients and mapped 48 VTs with VIVO and standard of\ncare electroanatomical mapping systems to determine accuracy. The study\n(https://www.globenewswire.com/Tracker?data=heLYyIbgQvi7QEJlN6JmiwrYVOuDhWXvjNS7CwhlVXUY3MqfOt03QkwS1-PuUv_BOdMaZnG9YEX3Q09r0LUC_llZlbHpu1hDa_VXXQ49cGc2o5kmbDo97vNEmooqOhasM_1P_OK-qRfcifyFgSmh0krZ0cQzpW_ZURU6OWHsQWvDuOGg5ZoGF0R9tVHRxpCE)\nconcluded that VIVO can accurately predict the arrhythmogenic substrate for\nscar-dependent VT and incorporation of VIVO mapping to conventional VT\nablation workflows improves procedural efficiency.\n\nDavid Jenkins, CEO of Catheter Precision, said, “Having an abstract accepted\nat any conference is an accomplishment. Somewhere around 50% of abstracts are\naccepted and knowing that this is the largest submission of ground-breaking\ndata ever at HRS means that the research and products resonate with the\nabstract committee. Further, to have one of our VIVO users be asked to present\na session highlights the excitement around not just the product, but the\nbenefits that VIVO brings to patients, hospitals and physicians. We anticipate\nHRS 2026 to be a symposium where we not only demonstrate our products to new\nand existing customers, but where we can share new and exciting research, like\nthe new peer reviewed publications, that validate our products to the EP\ncommunity.”\n\nAbout LockeT\nCatheter Precision’s LockeT is a suture retention device intended to assist\nin wound closure after percutaneous venous punctures. LockeT is a Class 1\ndevice registered with the FDA.\n\nAbout VIVO\nCatheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive\n3D imaging system that enables physicians to identify the origin of\nventricular arrhythmias pre-procedure, thereby streamlining workflow and\nreducing procedure time. VIVO has received marketing clearance from the U.S.\nFDA and has the CE mark.\n\nAbout Catheter Precision\nCatheter Precision is an innovative U.S.-based medical device company bringing\nnew solutions to market to improve the treatment of cardiac arrhythmias. It is\nfocused on developing groundbreaking technology for electrophysiology\nprocedures by collaborating with physicians and continuously advancing its\nproducts.\n\nCautionary Note Regarding Forward-Looking Statements\nStatements in this press release may contain “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995\nthat are subject to substantial risk and uncertainties. Forward-looking\nstatements can be identified by words such as “believe,” “anticipate,”\n“may,” “might,” “can,” “could,” “continue,” “depends,”\n“expect,” “expand,” “forecast,” “intend,” “predict,”\n“plan,” “rely,” “should,” “will,” “may,” “seek,” or\nthe negative of these terms and other similar expressions, although not all\nforward-looking statements contain these words.  These forward-looking\nstatements include, but are not limited to, statements regarding our\nanticipation HRS 2026 will be a symposium where we not only demonstrate our\nproducts to new and existing customers, but where we can share new and\nexciting research, like the new peer-reviewed publications, that validate our\nproducts to the EP community. The Company’s expectations and beliefs\nregarding these matters may not materialize. Actual outcomes and results may\ndiffer materially from those contemplated by these forward-looking statements\nas a result of uncertainties, risks and changes in circumstances, including\nbut not limited to risks and uncertainties included under the caption “Risk\nFactors” in the Company’s Form 10-K filed with the SEC and available at\nwww.sec.gov.\n\nThe forward-looking statements included in this communication are made only as\nof the date hereof. The Company assumes no obligation and does not intend to\nupdate these forward-looking statements, except as required by law.\n\nCONTACTS:\n\nAt the Company\nDavid Jenkins\n973-691-2000\nIR@catheterprecision.com\n\n# # #\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cb9f10dc-be78-4c7c-a235-81bfdd77f03c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-23T16:00:00.516127078Z","server_sent_at_ms":1776960000516},"received_at":"2026-04-23T16:00:00.576Z","source_url":null},"analysis":{"id":"5392","press_release_id":"7199","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Catheter Precision will present new clinical data on its VIVO system at the 47th Annual Heart Rhythm Society meeting and announced the acceptance of two peer-reviewed publications for its products.\n\nThe accepted studies include a LockeT trial involving 139 patients that demonstrated high procedural success, and a VIVO study of 31 patients that showed improved accuracy in identifying ventricular tachycardia origins.\n\nCEO David Jenkins highlighted that the acceptance of abstracts at the conference, which saw record submissions, validates the company's research and the benefits of its technology for the EP community.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Peer-reviewed publications and HRS data presentation reinforce clinical utility of VIVO and LockeT."},"keyFigures":{"customDimensions":{"vivo_vts_mapped":48,"vivo_study_patients":31,"locket_study_patients":139}},"quotedText":"Having an abstract accepted at any conference is an accomplishment. Somewhere around 50% of abstracts are accepted and knowing that this is the largest submission of ground-breaking data ever at HRS means that the research and products resonate with the abstract committee.","namedEntities":{"people":[{"name":"David Jenkins","role":"CEO"},{"name":"Tarvinder Dhanjal","role":"Professor"}],"products":["VIVO","LockeT"],"companies":[{"name":"Catheter Precision, Inc.","ticker":"VTAK"},{"name":"Heart Rhythm Society","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Presentation of positive feasibility data and acceptance of peer-reviewed publications for both VIVO and LockeT products provide clinical validation and market awareness, though the event lacks immediate binary regulatory or revenue impact."},"tickerRelevance":{"others":[],"primary":"VTAK"},"eventTypeSecondary":[]},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Catheter Precision will present new clinical data on its VIVO system at the 47th Annual Heart Rhythm Society meeting and announced the acceptance of two peer-reviewed publications for its products.\n\nThe accepted studies include a LockeT trial involving 139 patients that demonstrated high procedural success, and a VIVO study of 31 patients that showed improved accuracy in identifying ventricular tachycardia origins.\n\nCEO David Jenkins highlighted that the acceptance of abstracts at the conference, which saw record submissions, validates the company's research and the benefits of its technology for the EP community.","key_figures":{"customDimensions":{"vivo_vts_mapped":48,"vivo_study_patients":31,"locket_study_patients":139}},"named_entities":{"people":[{"name":"David Jenkins","role":"CEO"},{"name":"Tarvinder Dhanjal","role":"Professor"}],"products":["VIVO","LockeT"],"companies":[{"name":"Catheter Precision, Inc.","ticker":"VTAK"},{"name":"Heart Rhythm Society","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-23T21:50:37.359Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:55.048Z"}},"durationMs":172099,"modelName":"glm-4.7"}}